Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $10.40.

Several equities research analysts recently issued reports on IRWD shares. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target on the stock. Wells Fargo & Company lowered their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Capital One Financial lowered Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. Finally, Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $4.02 on Tuesday. The firm has a 50 day simple moving average of $4.27 and a two-hundred day simple moving average of $5.45. Ironwood Pharmaceuticals has a one year low of $3.79 and a one year high of $15.70. The company has a market cap of $642.15 million, a P/E ratio of -134.00 and a beta of 0.47.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same period last year, the firm posted $0.12 EPS. Ironwood Pharmaceuticals’s quarterly revenue was down 19.4% on a year-over-year basis. On average, analysts expect that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Texas Permanent School Fund Corp increased its position in Ironwood Pharmaceuticals by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock valued at $1,047,000 after purchasing an additional 1,557 shares during the period. CWM LLC increased its position in shares of Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after buying an additional 2,345 shares during the period. Louisiana State Employees Retirement System raised its stake in Ironwood Pharmaceuticals by 3.5% during the second quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock worth $459,000 after buying an additional 2,400 shares during the last quarter. SummerHaven Investment Management LLC lifted its holdings in Ironwood Pharmaceuticals by 3.6% in the second quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 2,491 shares during the period. Finally, Rhumbline Advisers boosted its position in Ironwood Pharmaceuticals by 0.7% during the second quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock valued at $2,384,000 after acquiring an additional 2,577 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.